Log in

Dechra Pharmaceuticals Share Forecast, Price & News

GBX 3,482
+8.00 (+0.23 %)
(As of 10/20/2020 09:55 AM ET)
Today's Range
Now: GBX 3,482
50-Day Range
MA: GBX 3,257.08
52-Week Range
Now: GBX 3,482
Volume6,527 shs
Average Volume264,638 shs
Market Capitalization£3.76 billion
P/E Ratio106.16
Dividend Yield1.02%
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for dogs and cats under the Specific brand; distributes veterinary pharmaceuticals and equipment; and offers financial services. The company markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More
Dechra Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Major



Sales & Book Value

Annual Sales£515.10 million
Cash FlowGBX 210.74 per share
Book ValueGBX 590.20 per share



Market Cap£3.76 billion
Next Earnings DateN/A
OptionableNot Optionable
GBX 3,482
+8.00 (+0.23 %)
(As of 10/20/2020 09:55 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions

How has Dechra Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Dechra Pharmaceuticals' stock was trading at GBX 2,472 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DPH shares have increased by 40.9% and is now trading at GBX 3,482.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Dechra Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Dechra Pharmaceuticals

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals announced a dividend on Monday, September 7th. Stockholders of record on Thursday, November 5th will be given a dividend of GBX 24 per share on Friday, November 27th. This represents a yield of 0.73%. The ex-dividend date is Thursday, November 5th. This is a boost from Dechra Pharmaceuticals's previous dividend of GBX 10.29. The official announcement can be seen at this link.
View Dechra Pharmaceuticals' dividend history

What price target have analysts set for DPH?

4 brokers have issued 1-year target prices for Dechra Pharmaceuticals' shares. Their forecasts range from GBX 2,510 to GBX 3,515. On average, they expect Dechra Pharmaceuticals' share price to reach GBX 3,077.50 in the next year. This suggests that the stock has a possible downside of 11.6%.
View analysts' price targets for Dechra Pharmaceuticals

Who are some of Dechra Pharmaceuticals' key competitors?

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include (TTR.L) (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SkyePharma (SKP) and Barratt Developments plc (BDEV.L) (BDEV).

Who are Dechra Pharmaceuticals' key executives?

Dechra Pharmaceuticals' management team includes the following people:
  • Mr. Ian D. Page, CEO, MD & Exec. Director (Age 58)
  • Mr. Richard John Cotton, CFO & Director (Age 58)
  • Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 56)
  • Ms. Katy Clough, Group HR Director
  • Mr. Mike Eldred, Pres of North America (Age 49)

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 3,482.

How big of a company is Dechra Pharmaceuticals?

Dechra Pharmaceuticals has a market capitalization of £3.76 billion and generates £515.10 million in revenue each year. Dechra Pharmaceuticals employs 1,437 workers across the globe.

What is Dechra Pharmaceuticals' official website?

The official website for Dechra Pharmaceuticals is www.dechra.com.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.